Invivyd, Inc. (IVVD)
| Market Cap | 180.81M -54.7% |
| Revenue (ttm) | 58.37M +26.3% |
| Net Income | -107.33M |
| EPS | -0.40 |
| Shares Out | 294.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,762,840 |
| Open | 0.5920 |
| Previous Close | 0.6101 |
| Day's Range | 0.5800 - 0.6213 |
| 52-Week Range | 0.5277 - 3.0700 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+1,530.26%) |
| Est. Earnings | Nov 5, 2026 |
About IVVD
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatmen... [Read more]
Financial Performance
In 2025, Invivyd's revenue was $53.43 million, an increase of 110.47% compared to the previous year's $25.38 million. Losses were -$52.49 million, -69.11% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 1,530.26% from the latest price.
News
Invivyd presents measles antibody candidate VMS063 data at IDWeek 2026
Invivyd (IVVD) announced the presentation of preclinical data describing its novel, potential first- and best-in-class investigational monoclonal antibody candidate VMS063 at IDWeek 2026 in Washington...
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary m...
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the initiation of FLINTLOCK, a Phase 2 clinical trial evaluating the safety, ...
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an...
Invivyd Phase 3 data supports VYD2311 tolerability, says H.C. Wainwright
Invivyd’s (IVVD) Phase 3 LIBERTY data strengthen VYD2311’s vaccine-alternative positioning, with significantly better safety and tolerability versus COMIRNATY and roughly 2.5x higher neutralizing tite...
Invivyd Transcript: Study result
LIBERTY found significantly lower adverse-event burden with VYD2311 than mRNA vaccination, with no detected interference when combined. DECLARATION is expected to provide placebo-controlled safety and immunogenicity data supporting a potential accelerated-approval filing.
Invivyd Press release: Study result
Invivyd issued a press release on September 29, 2026, disclosing material business information to investors.
Invivyd Slides: Study result
Invivyd has posted slides in relation to its latest quarterly earnings report, which was published on September 29, 2026.
Invivyd announces results from LIBERTY Phase 3 study of VYD2311
Invivyd (IVVD) announced positive, clinically meaningful, and statistically significant topline data from the LIBERTY Phase 3, an active controlled study evaluating the safety and tolerability of VYD2...
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, clinically meaningful, and statistically significant topline data from the LIBERTY Phase 3, ...
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
Invivyd Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The discussion highlighted advances in monoclonal antibody technology for infectious disease prevention, with VYD2311 poised for broader use and regulatory decisions pending. Flexible dosing, strong efficacy targets, and significant market potential were emphasized, alongside a strategic focus on consumer engagement and long-term growth.
Invivyd management to meet virtually with BTIG
Biotechnology Analyst Shrader holds a virtual meeting with management on September 11 at 9 am hosted by BTIG.
Invivyd to Participate in Upcoming September Investor Conferences
NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will partic...
Cantor says Invivyd should be trading ‘meaningfully higher’ after update
Cantor Fitzgerald notes that Invivyd (IVVD) announced the long-awaited appointment of Chairman Marc Elia to the role of CEO and the company also reframed the pending analysis of the Phase…
Invivyd appoints Marc Elia as CEO
Invivyd (IVVD) announced that the company has appointed Marc Elia, current chairman of the Invivyd board of directors, as CEO of the company. He will serve as chairman and CEO…
Invivyd provides update on VYD2311 program, DECLARATION study
Invivyd (IVVD) continues to expect top-line data from the VYD2311 program around the end of Q3. At that time, Invivyd plans to either unblind the DECLARATION study in its entirety…
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as Chief...
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
NEW HAVEN, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights.
Invivyd Earnings release: Q2 2026
Invivyd released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Invivyd Quarterly report: Q2 2026
Invivyd has published its Q2 2026 quarterly earnings report on August 13, 2026.
Invivyd announces notice of termination for Pemgarda Emergency Use Authorization
Invivyd (IVVD) announced that the FDA has sent Invivyd a notice of termination for the Pemgarda Emergency Use Authorization, or EUA, following the U.S. Department of Health and Human Services’,…
Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
NEW HAVEN, Conn., July 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has sent Invivyd a Notice of Termination for the PEMGA...
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an agg...
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for ar...